Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Amarin Corporation plcNASDAQ: AMRN
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$3, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$16.69M.
Context
- Capital expenditures amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Capital expenditures increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near -$3 or moves back toward the trailing-twelve-month quarterly average of -$4.17M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 2 | +100.0% |
| FY2023 | 2023-12-31 | (24.1K) | -1277352.7% |
| FY2022 | 2022-12-31 | (2) | -178.2% |
| FY2021 | 2021-12-31 | 2 | — |
Capital Expenditures vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +140168207.3% is the highest of 9, against a peer median of -26.2%.
- Capital expenditures amounts to 7.8% of revenue for AMRN, versus a peer median of 18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.69M USD | +140168207.3% | — | 7.8% | |
| LTM Mar 2026 | $2.23M USD | -44.0% | -1.0% | 3.3% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $1.39M USD | +138.4% | +113.3% | — |
| LTM Mar 2026 | $928K USD | -8.4% | -10.9% | — | |
| LTM Dec 2025 | CHF 900.16K CHF | +56.3% | -11.5% | 25.2% | |
| LTM Mar 2026 | $623K USD | -8.4% | -68.2% | 2009.7% | |
| LTM Mar 2026 | $556K USD | -70.3% | -68.0% | — | |
| LTM Mar 2026 | $420K USD | -96.6% | -53.7% | 10.9% | |
| LTM Mar 2026 | $106K USD | — | -53.4% | 11.5% | |
| LTM Mar 2026 | $42K USD | -92.6% | -3.1% | — | |
| LTM Mar 2026 | $32K USD | — | -55.6% | 88.9% | |
| Peer median (excluding AMRN) | — | -26.2% | -32.5% | 18.3% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73M | (105.74M) | (59.34M) | (82.18M) | (38.8M) |
| Depreciation & Amortization | 2.86M | 3.09M | 2.98M | 3.01M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 17.71M | 13.94M |
| Change in Working Capital | (115.98M) | (104.01M) | 51.27M | 36.17M | 32.28M |
| Accounts Receivables | (8.34M) | 32.98M | (2.33M) | 11.22M | (3.83M) |
| Inventory | (167.05M) | (36.4M) | 56.34M | 105.44M | 34.96M |
| Accounts Payables | 51.51M | (102.67M) | (164.64K) | (77.02M) | 14.54M |
| Other Working Capital | 7.9M | 2.07M | (2.56M) | (3.5M) | (13.39M) |
| Other Non-Cash Items | 38.86M | 26.67M | 12M | (5.73M) | (3.71M) |
| Operating Cash Flow | (66.53M) | (179.98M) | 6.91M | (31.03M) | 6.74M |
| Capital Expenditures | 2 | (2) | (24.1K) | 2 | 0 |
| Acquisitions (Net) | 4K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (290.16M) | (81.58M) | (215.93M) | (278.78M) | (200.94M) |
| Sales of Investments | 394.25M | 257.36M | 190.84M | 232.8M | 209.79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 104.09M | 175.18M | (25.62M) | (45.98M) | 8.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.57M | 664.59K | 2.22M | 131.06K | 140.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.64M) | (1.04M) | (1.99M) | (1.57M) | (2.18M) |
| Financing Cash Flow | (5.07M) | (378.77K) | 230.89K | (1.44M) | (2.04M) |
| Effect of Forex Changes | 3.87K | (3.2K) | 71.37K | 33.01K | (31.6K) |
| Net Change in Cash | 32.49M | (5.18M) | (18.41M) | (78.44M) | 13.52M |
| Free Cash Flow | (66.53M) | (179.98M) | 6.88M | (31.02M) | 6.74M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.